Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Holly K KoblishLiangxing WuLiang-Chuan S WangPhillip C C LiuRichard WynnJonathan Rios-DoriaSusan SpitzHao LiuAlla VolginaNina ZolotarjovaKanishk KapilashramiElham BehshadMaryanne CovingtonYan-Ou YangJingwei LiSharon DiamondMaxim SolovievKevin O'HayerStephen RubinChrysi KanellopoulouGengjie YangMark RuparDarlise DiMatteoLuping LinChristina StevensYue ZhangPramod ThekkatRyan GeschwindtCindy MarandoSwamy YeleswaramJeff JacksonPeggy ScherleReid HuberWenqing YaoGregory HollisPublished in: Cancer discovery (2022)
We have identified a potent small-molecule inhibitor of PD-L1, INCB086550, which has biological properties similar to PD-L1/PD-1 monoclonal antibodies and may represent an alternative to antibody therapy. Preliminary clinical data in patients demonstrated increased immune activation and tumor growth control, which support continued clinical evaluation of this approach. See related commentary by Capparelli and Aplin, p. 1413. This article is highlighted in the In This Issue feature, p. 1397.